Fund life-saving treatment for St. Albert toddler now: Forsyth

CALGARY, AB (August 2, 2013): The PC government needs to immediately commit to funding a life-saving drug for a three-year-old Alberta girl with an extremely rare, life-threatening disease, Wildrose Health Critic Heather Forsyth said today.

The girl, Aleena Sadownyk of St. Albert, was diagnosed in April with MPS VI, an enzyme deficiency disease that occurs in one out of approximately 250,000 to 600,000 newborn babies. If left untreated, it will cause life-threatening complications including heart problems, breathing difficulties and skeletal deformations.

The treatment, Naglazyme, has proven successful in other patients suffering from MPS VI, including seven other Canadian children who are currently receiving this treatment in neighbouring provinces. It costs approximately $300,000 annually. BC, Saskatchewan, Ontario and Quebec have all agreed to fund Naglazyme for MPS VI patients.

Today, Forsyth sent a letter to Health Minister Fred Horne formally requesting he approve funding for Aleena’s treatment.

“This treatment is Aleena’s only hope,” Forsyth said. “Today, I join with the Sadownyk family in making this simple but critical request of the Alberta government: Please fund this life-saving treatment for Aleena.”

Forsyth said the Sadownyk family has attempted to raise Aleena’s extraordinary case with their local MLA and with Horne but has had little success. The government has already denied the family’s first funding request through the Alberta Rare Diseases Funding Program. A second request through the Short Term Exceptional Drug Therapy Program has received no response.

“This family is desperate to save their daughter’s life,” Forsyth said. “Aleena needs this treatment and she needs it now. Every day that access is delayed, is another day for irreversible complications to take hold. Other provinces have stepped up when their children needed this treatment. It’s time for Alberta to do the same.”

Heather Forsyth
Calgary-Fish Creek
Heather Forsyth was first elected on June 15, 1993 as the MLA for Calgary-Fish Creek, and acts as the Wildrose Health critic.

Source: http://www.wildrose.ca/feature/fund-life-saving-treatment-for-st-albert-toddler-now-forsyth/ 

 

Parents want province to fund treatment for child's rare condition

Aleena Sadowynk, 3, has a rare enzyme deficiency CBC News

Posted: Aug 2, 2013 9:52 PM MT

Last Updated: Aug 2, 2013 9:50 PM MT


A couple from St. Albert is trying to get Alberta Health to cover the expensive medication to treat their daughter’s rare medical disorder.

Aleena Sadownyk, 3, suffers from the enzyme deficiency MPS VI, a condition with fewer than ten cases in Canada.

The MPS VI is treated with an drug called Naglazyme, which can cost anywhere from $300,000 to $1 million each year.

Aleena’s parents Dane and Laura Sadownyk applied for funding months ago but were turned down because because Health Canada hadn’t given Naglazyme general market approval.

They are now awaiting a reply from Alberta Health after applying under the Short Term Exceptional Drug Therapy Program.

“We’re not taking not taking no as an answer. If we have to contact every person out there to tweet, Facebook, email, phone, [Health] Minister [Fred] Horne, we’ll do that, ” Laura Sadownyk said.

“We have lots of people supporting us and we need the support of the public.”

“It’s a child’s life. That’s the bottom line,” Dane Sadownyk said. “She deserves a future like any other child should and that’s all we want for her.”

Aleena’s case is now being reviewed by medical experts who will determine whether the drug can be funded.

In a statement sent to CBC News, Horne suggested that the delay has been caused by the fact Naglazyme doesn’t have general market approval from Health Canada.

“Because it doesn’t have federal approval, the options for funding this drug are different than for some other drugs,” he said.

Parents want province to fund treatment for child’s rare condition

Aleena Sadowynk, 3, has a rare enzyme deficiency CBC News

Posted: Aug 2, 2013 9:52 PM MT

Last Updated: Aug 2, 2013 9:50 PM MT


A couple from St. Albert is trying to get Alberta Health to cover the expensive medication to treat their daughter’s rare medical disorder.

Aleena Sadownyk, 3, suffers from the enzyme deficiency MPS VI, a condition with fewer than ten cases in Canada.

The MPS VI is treated with an drug called Naglazyme, which can cost anywhere from $300,000 to $1 million each year.

Aleena’s parents Dane and Laura Sadownyk applied for funding months ago but were turned down because because Health Canada hadn’t given Naglazyme general market approval.

They are now awaiting a reply from Alberta Health after applying under the Short Term Exceptional Drug Therapy Program.

“We’re not taking not taking no as an answer. If we have to contact every person out there to tweet, Facebook, email, phone, [Health] Minister [Fred] Horne, we’ll do that, ” Laura Sadownyk said.

“We have lots of people supporting us and we need the support of the public.”

“It’s a child’s life. That’s the bottom line,” Dane Sadownyk said. “She deserves a future like any other child should and that’s all we want for her.”

Aleena’s case is now being reviewed by medical experts who will determine whether the drug can be funded.

In a statement sent to CBC News, Horne suggested that the delay has been caused by the fact Naglazyme doesn’t have general market approval from Health Canada.

“Because it doesn’t have federal approval, the options for funding this drug are different than for some other drugs,” he said.

Tot's treatment for rare illness not covered by Alberta's government

‘The provincial government has the opportunity to do the right thing…’: family friend

BY  ,EDMONTON SUN

FIRST POSTED: | UPDATED: 

Aleena Sadownyk
St. Albert Toddler Diagnosed With Ultra-Rare Condition; Treatment Already Being Funded In Numerous Provinces Alberta Health is currently considering an application for exceptional funding of an expensive life-sustaining treatment required by an Alberta toddler. Three year-old Aleena Sadownyk was recently diagnosed with MPS VI, and requires the life-sustaining treatment immediately in order to halt further progression of her devastating disease. Alberta Health has already denied funding for the treatment through the Alberta Rare Diseases Funding Program. They are now reviewing a second application through the Short Term Exceptional Drug Therapy (STEDT) program. While Aleena needs to begin treatment immediately, there has been no timeline set for a decision from Alberta Health. Family Hand Out Photo

Three-year-old Aleena Sadownyk was recently diagnosed with a rare and fatal enzyme deficiency called Maroteaux-Lamy Syndrome or MPS VI.

The toddler is already experiencing serious symptoms — Aleena’s hands and shoulder joints have begun to seize up — and without treatment officials say the disease is likely a death sentence.

“Left untreated, children have a severely shortened life-span,” said family-friend Andrew McFayden.

“There are varying degrees of progression in children and right now it’s suspected that Aleena has a rapidly progressive form.”

McFayden is a new friend of Aleena’s parents — Laura and Dane Sadownyk.

The Sadownyk’s reached out to McFadyen after they learned about his son Isaac — who lives with the same disease their daughter was diagnosed with — and McFadyen’s fight to have the Ontario government foot his treatment bill.

Individuals with MPS VI require an enzyme replacement therapy that can cost up to $1 million per year, and the treatment must be continued once a week for the rest of their lives.

It’s already covered by provincial health care in Ontario — where McFadyen battled to have the treatment brought to Canada using the Federal Government’s Special Access Program (SAP) and paid for by the province, as well as in British Columbia, Saskatchewan and Quebec.

Now, McFadyen is hell-bent on helping Aleena get the treatment that has allowed his son — who was crippled with spinal pressure and enlarged internal organs — to burst through their back door today at a full run.

“As I’m talking to you right now he’s racing outside to play with his brothers,” said McFadyen, of Isaac, 9, who has been receiving the treatments for seven years now.

“The damage that was done to his spine, bones and joints can’t be reversed but there has been no further build up of disease.”

Though he’s grateful it wasn’t worse, he doesn’t want to see Aleena left with the same life-long damage.

“Aleena is waiting to begin treatment – her hands are beginning to claw up, she can’t lift her shoulders above her head, that’s the latest,” he said. “She needs to start treatment in order to halt any further deterioration.”

According to McFadyen — who runs a charity called the Isaac Foundation — Alberta Health has already denied funding for the treatment through the Alberta Rare Diseases Funding Program.

But officials are currently revising a second application through the Short Term Exceptional Drug Therapy (STEDT) program — with no timeline set for a decision.

It’s time Aleena doesn’t have, and McFadyen says his hope is for Premier Alison Redford to step up and expedite the process.

“The provincial government has the opportunity to do the right thing and ensure that Aleena receives the treatment she so desperately needs,” he said.

“Parents should not have to put their children’s faces on the front of newspapers in order to get the treatment they deserve.”

angelique.rodrigues@sunmedia.ca

Tot’s treatment for rare illness not covered by Alberta’s government

‘The provincial government has the opportunity to do the right thing…’: family friend

BY  ,EDMONTON SUN

FIRST POSTED: | UPDATED: 

Aleena Sadownyk
St. Albert Toddler Diagnosed With Ultra-Rare Condition; Treatment Already Being Funded In Numerous Provinces Alberta Health is currently considering an application for exceptional funding of an expensive life-sustaining treatment required by an Alberta toddler. Three year-old Aleena Sadownyk was recently diagnosed with MPS VI, and requires the life-sustaining treatment immediately in order to halt further progression of her devastating disease. Alberta Health has already denied funding for the treatment through the Alberta Rare Diseases Funding Program. They are now reviewing a second application through the Short Term Exceptional Drug Therapy (STEDT) program. While Aleena needs to begin treatment immediately, there has been no timeline set for a decision from Alberta Health. Family Hand Out Photo

Three-year-old Aleena Sadownyk was recently diagnosed with a rare and fatal enzyme deficiency called Maroteaux-Lamy Syndrome or MPS VI.

The toddler is already experiencing serious symptoms — Aleena’s hands and shoulder joints have begun to seize up — and without treatment officials say the disease is likely a death sentence.

“Left untreated, children have a severely shortened life-span,” said family-friend Andrew McFayden.

“There are varying degrees of progression in children and right now it’s suspected that Aleena has a rapidly progressive form.”

McFayden is a new friend of Aleena’s parents — Laura and Dane Sadownyk.

The Sadownyk’s reached out to McFadyen after they learned about his son Isaac — who lives with the same disease their daughter was diagnosed with — and McFadyen’s fight to have the Ontario government foot his treatment bill.

Individuals with MPS VI require an enzyme replacement therapy that can cost up to $1 million per year, and the treatment must be continued once a week for the rest of their lives.

It’s already covered by provincial health care in Ontario — where McFadyen battled to have the treatment brought to Canada using the Federal Government’s Special Access Program (SAP) and paid for by the province, as well as in British Columbia, Saskatchewan and Quebec.

Now, McFadyen is hell-bent on helping Aleena get the treatment that has allowed his son — who was crippled with spinal pressure and enlarged internal organs — to burst through their back door today at a full run.

“As I’m talking to you right now he’s racing outside to play with his brothers,” said McFadyen, of Isaac, 9, who has been receiving the treatments for seven years now.

“The damage that was done to his spine, bones and joints can’t be reversed but there has been no further build up of disease.”

Though he’s grateful it wasn’t worse, he doesn’t want to see Aleena left with the same life-long damage.

“Aleena is waiting to begin treatment – her hands are beginning to claw up, she can’t lift her shoulders above her head, that’s the latest,” he said. “She needs to start treatment in order to halt any further deterioration.”

According to McFadyen — who runs a charity called the Isaac Foundation — Alberta Health has already denied funding for the treatment through the Alberta Rare Diseases Funding Program.

But officials are currently revising a second application through the Short Term Exceptional Drug Therapy (STEDT) program — with no timeline set for a decision.

It’s time Aleena doesn’t have, and McFadyen says his hope is for Premier Alison Redford to step up and expedite the process.

“The provincial government has the opportunity to do the right thing and ensure that Aleena receives the treatment she so desperately needs,” he said.

“Parents should not have to put their children’s faces on the front of newspapers in order to get the treatment they deserve.”

angelique.rodrigues@sunmedia.ca

St. Albert family hopes province will pay for child’s expensive medical treatment

Toddler already slowed by rare disorder that worsens without therapy

BY JODIE SINNEMA, EDMONTON JOURNAL AUGUST 2, 2013
St. Albert family hopes province will pay for child’s expensive medical treatment

Aleena Sadownyk has a rare enzyme deficiency called MPS VI that causes buildup of cellular waste in their body. They need a synthetic form of the enzyme to be injected each week. Supplied by family

Photograph by: Greg Southam

St. Albert – Inside Aleena Sadownyk’s three-year-old body, cellular waste is building up in her finger joints, around a heart valve and enlarging her liver and spleen.

Without a crucial enzyme in her body called glycosaminoglycan to break down that waste, it will continue to build up, restricting her movements, clouding her eyesight and damaging her organs. Without treatment, her life expectancy will dwindle.

Aleena is already exhausted, passed out on the couch of her St. Albert home as her parents tell her story in the hopes the provincial government will listen and fund her $300,000 – to $1-million annual treatment.

Her cause is being championed by Wildrose MLA and health critic Heather Forsyth who has written the government asking it to help.

“It’s devastating,” said her father Dane Sadownyk, speaking both of his daughter’s diagnosis of the rare Maroteaux-Lamy Syndrome and of waiting for the provincial health department to review the case and decide if it will cover the cost.

“You’re on pins and needles,” Dane said. “You know there’s a treatment there and it’s just a matter of her being able to receive it.”

While there is no cure, a synthetic enzyme called Naglazyme is approved in the United States. Through weekly hours-long infusions, Naglazyme can break down the cellular waste building in up a patient’s body. Patients need to be on the enzyme-replacement therapy for life, but symptoms won’t worsen.

Even though it isn’t yet approved for use in Canada, seven other children with MPS VI are receiving the treatment after their families successfully lobbied their governments in B.C., Saskatchewan, Ontario and Quebec to cover the cost. The provinces only gave coverage after public awareness campaigns, said Andrew McFadyen, whose son Isaac was diagnosed when he was 18 months old.

It took six months to get funding for Isaac’s treatment which stopped the progression of the disorder, made his skin and hair soft again, and shrunk down his swollen organs. But the treatment won’t reverse the damage already done to Isaac’s eyes, give his shoulders full range of motion or allow his hands to make a fist, since his fingers clawed up.

“It was tough,” McFadyen said from Ontario. The Sadownyk family contacted him for help when their request for funding through the Alberta Rare Disease Funding Program was turned down. “The only thing that works is public advocacy campaigns. Once the public understands that the public health system has the ability to look after a very sick child and they’re not, then action gets demanded.”

Isaac is now nine and heading into Grade 4. This type of enzyme deficiency doesn’t cause compounds to build up in the brain. McFadyen wants Aleena to have a chance to grow up too.

“I have all the hope in the world that this will shift things and prompt a decision,” he said.

The province currently has a funding application from the family through the Short-term Exceptional Drug Therapy Program, which provides six months of treatment.

“My heart goes out to the Sadownyk family. I know they want to do everything they can to help their daughter,” Health Minister Fred Horne said in a statement. “As a politician, I don’t get directly involved in assessing which drugs would be funded through that process — and appropriately leave that assessment to medical experts. Department officials will continue to support the application process, a clinical review is underway now and I understand we expect a response soon.”

It can’t come soon enough for the Sadownyks. Aleena was in gymnastics this past spring and couldn’t grip the bars or kneel on all fours because of stiffness in her hands and knees. Nor can she properly grasp a crayon.

“It’s traumatizing for her,” said her mother Laura Sadownyk. Aleena doesn’t fully understand her condition, but she certainly doesn’t enjoy all the doctor appointments.

“We don’t know how fast it will progress in her,” Laura said. “We need the minister to accept the funding request.”

jsinnema@edmontonjournal.com

twitter.com/jodiesinnema

© Copyright (c) The Edmonton Journal

Alberta Toddler Awaiting Funding For Life Sustaining Treatment

ALBERTA TODDLER AWAITING FUNDING FOR LIFE-SUSTAINING TREATMENT

St. Albert Toddler Diagnosed With Ultra-Rare Condition; Treatment Already Being Funded In Numerous Provinces

Alberta Health is currently considering an application for exceptional funding of an expensive life-sustaining treatment required by an Alberta toddler.  Three year-old Aleena Sadownyk was recently diagnosed with MPS VI, and requires the life-sustaining treatment immediately in order to halt further progression of her devastating disease.  Alberta Health has already denied funding for the treatment through the Alberta Rare Diseases Funding Program.  They are now reviewing a second application through the Short Term Exceptional Drug Therapy (STEDT) program.  While Aleena needs to begin treatment immediately, there has been no timeline set for a decision from Alberta Health.

Aleena suffers from a rare enzyme deficiency called MPS VI (also known as Maroteaux-Lamy Syndrome).  Sufferers of MPS VI lack an enzyme in their blood that breaks down cellular waste in the body called glycosaminoglycan (GAG).  These GAGs build up in the bones, tissues, organs, and muscles of affected individuals and lead to many devastating symptoms including heart and airway disease, corneal clouding, stiffening of the joints, shortened stature, and premature death.  To date, there are 9 children suffering from the disease in Canada and roughly 1,100 worldwide.

While there is no known cure for MPS VI, a treatment does exist.  Naglazyme is an Enzyme-Replacement Therapy (ERT) designed to provide patients with a synthetic version of the enzyme they are lacking by infusing small doses into the patient’s bloodstream on a weekly basis.  Produced by Biomarin, the treatment for this orphan disease can range from $300,000 per year for a small individual to $1 million per year for a young adult.  Due to the lack of an orphan drug policy in Canada, Naglazyme is only available to Canadian patients through the Federal Government’s Special Access Program (SAP).  It is being used for patients in Ontario, British Columbia, Saskatchewan, and Quebec through the SAP and is funded by the Provincial governments respectively.  Currently, Naglazyme has been approved in numerous countries worldwide, including the United States, the European Union, and Australia.

In Canada, there are numerous precedents for the life-sustaining treatment to be funded.  The first approved case took place in Ontario where the parents of 9 year-old Isaac McFadyen, residents of Campbellford, Ontario, successfully lobbied the Government to fund the expensive Enzyme Replacement Therapy for him when he was diagnosed in 2006.  After a very public campaign to secure funding, Isaac has been receiving his weekly infusions at The Hospital For Sick Children in Toronto for 7 years.  Since then, numerous other provinces have used the precedent set by the McFadyen case and have approved the same treatment for their patients, most recently in 2012 in Saskatchewan and 2011 in Ontario.

Prior to starting treatment, Isaac suffered from severe compression of his spinal cord that required the removal of a piece of his skull and a portion of his vertebrae.  In addition, Isaac endured numerous other surgeries to treat complications of the advancing disease in his body.   Since beginning his weekly infusions, Isaac’s liver and spleen have reduced back down to a normal size, his rate of growth has increased, his heart function has improved, and his heart valve disease has stabilized.  Furthermore, Isaac has had no further progression of his bone and joint disease, airway disease, and compression of his spinal cord.

Naturally, the Sadownyk family has been devastated by the diagnosis of their daughter, Aleena.  Laura Sadownyk, Aleena’s mother, expressed her fears about the length of time the government is taking to render its decision.  “It’s very agonizing to wait patiently, especially after hearing the experts in this field talk about early diagnosis and treatment being the best way to prevent the onset of a lot of the effects of this disease.”

McFadyen also notes how important it is to get children affected with MPS VI started on weekly infusions at a young age, and is also frustrated by the process put in place to review rare disease funding in the province.  “We know that this treatment can slow down or even halt the disease progression in individuals so it’s very important to begin treatment as soon as possible after diagnosis.  Aleena has already been approved by the Special Access Program to receive the treatment she so desperately needs.  The only thing stopping her from beginning that treatment is the lack of funding by the Province.”  Adds Sadownyk, “It’s heartbreaking that the fate of our daughter rests in the hands of bureaucrats.”

McFadyen believes that the time for action from the Redford government is now.  “The Provincial government has the opportunity to do the right thing and ensure that Aleena receives the treatment she so desperately needs.  It’s the role of government to protect and ensure fair and equitable access to Health Care for all Canadians, regardless of which Province they happen to live it.  The Isaac Foundation is calling on this government to take action and save the life of this child.  She can’t afford to wait.”

#  #  #

For more information about this topic, or to schedule an interview to discuss, please call Andrew at 613-328-9136 or email Andrew at mcfadyena@me.com.

Attached Photo – Aleena Sadownyk, Age 3.  St. Albert, AB
4d5f8030f60e11e2ad2b22000ae80c6b_7

#Treatment4Aleena

photo 1-2Hi Everyone,

As a educator, I often look for ways to help our children become empathetic, caring, and compassionate individuals.  When kids leave my classroom, I want them to strive to make the world a better place; I want them to understand that they CAN make a difference in the greater world around them.  I want them to know the importance of helping others.

There are many ways that teachers help guide their students along the path to caring – books, news articles, projects, and fundraising activities all come to mind as examples I see in schools across this country.  All of these activities are well and good in the classroom, but none of it matters if we don’t stand in front of our children and lead by example.  None of it matters if our students don’t see us practicing what we’re preaching.  To me, taking a moment to fight to save the life of Aleena Sadownyk (pictured left) should be on top of everyone’s list of “To Do’s” today as we seek to set that example for our kids.

3 1/2 year old Aleena Sadownyk was recently diagnosed with an ultra-rare enzyme deficiency called MPS VI.  Essentially, Aleena lacks an enzyme in her blood responsible for breaking down cellular waste in her body.  This waste then builds up and stores in her bones, tissues, organs, and muscles.  Progressively, this disease devastates the body.  Internal organs begin to swell, joints begin to stiffen, and heart and airway disease begin to take over.  Along with a host of other catastrophic symptoms, this disease can lead to a shortened stature and a severely shortened life span.

isaac10lf4

When a child is diagnosed with this disease – and there are only 9 children fighting this in Canada – the news is devastating.  I know this because my son, Isaac (right), was diagnosed in 2006 at the age of 18 months.  At that time, we were told that our beautiful little boy may not reach his teens and that the years leading up to those teenage years would be filled with painful surgeries and horrific symptoms.  My wife and I were sick with fear – I lost 40 pounds in a few weeks, and we were devastated that the future for our little boy was forever changed.  At that time, Hope seemed lost.

However, we soon learned that Hope wasn’t lost.  A treatment for this disease was available, albeit not in Canada.  The treatment consists of a weekly infusion of a synthetic version of the enzyme that children affected with MPS VI lack.  Studies have shown that this treatment dramatically slows the progress of the disease, if not halt it altogether.  It’s not a cure, but it is certainly a lifeboat for our children until a cure can be found.  Because we lack an Orphan Drug Policy here in Canada, we had to apply to have this treatment brought to Canada using the Federal Government’s Special Access Program (SAP).  We were quickly granted the right to bring the treatment (ERT) to Canada – contingent on the province funding the administration of it to our Isaac.  And herein lies the problem – treatment costs for a small child can start around $300,000 annually and escalate to $1,000,000 for a young teenager.

photo 3-1

Through our heartfelt lobbying of the Ontario Liberal Government, assisted by the tireless advocacy of MPP Elizabeth Witmer, we were successful in securing funding for Isaac.  Today, because of his treatment, Isaac is a happy 9-year old boy who loves to read, play with his toys, play piano, and spend time with his best friend, his younger brother Gabriel.

The battle for Isaac’s life was won, a battle that should never have taken place in the first place.  With the success of Isaac’s fight, and the obvious benefits to the treatment that the government was now funding, it should have been easy for Aleena’s family to get a quick approval for the same treatment.  After all, our Health Care System is designed to provide Equal Access to All – we’re set up to ensure the best care for all Canadians regardless of age, gender, religious beliefs – regardless of anything.  To bolster the case for providing treatment, ERT is already funded in numerous provinces across Canada, including BC, Saskatchewan, Ontario, and Quebec.  As well, ERT is already approved in the United States, the European Union, Australia, and other developed countries!  In fact, treating MPS VI with ERT is the standard of care in these countries.

But on a few weeks ago, Aleena’s family got the heartbreaking news that the Alberta Government had denied funding for the Life-Sustaining treatment that Aleena needs – the exact same treatment they are currently funding for Isaac McFadyen in Ontario.  And Jasper More in Ontario.  And Violet Revet in Saskatchewan.  And the list goes on!  Aleena’s parents, and our family, were stunned by the news.  How can we allow this disease to ravage Aleena when we know we can stop it?

Thus began our battle anew, and we’ve had to cross  government officials again in order to advocate for the life of a little girl.  As a member of the federal Liberal Party, and as an aspiring Politician, I’ve talked at length about preserving our Social Safety Net – standing up for those in need, protecting the most vulnerable in our society, and fighting for what I believe in.  Doing the right thing is never easy, and working to save Aleena’s life is the right thing.  Whatever the cost, this is a step we need to take in order to ensure that Aleena gets the same opportunity that my son has had.  The same opportunity that Jasper has had…and Violet.  The same opportunity all Canadians have – the right to a long and healthy life, with the proper access to our health care system in her time of need.

photo 4

Over the coming days, we’re going to need help.  A decision on the second application to Alberta Health is expected soon.  How long?  We don’t know because we can’t get an accurate timeline as to when the decision making process will be complete.  Essentially, the fate of Aleena is in the hands of a few select bureaucrats who get to say yes or no to funding the life-sustaining treatment Aleena needs.  To everyone out there that has supported The Isaac Foundation throughout the years, please stand ready.  Ready to help us advocate, ready to make a difference for Aleena.  We’ll update more as things progress as to what you can do to help.

I’ll sign off this overly long (sorry!) blog update by explaining our Foundation Slogan.  We chose “Love, Laughter, and Hope” because our son gives us the first two each and every day.  But sometimes, all you have left is Hope.  Aleena and her Family need all the hope they can get these days, and I’ll thank you in advance for providing that.

With Thanks,

A.

This is little Aleena. She is from Alberta and has just been diagnosed with MPS VI. The Isaac Foundation will do everything we possibly can to ensure she starts the life-sustaining treatment she so desperately needs. #Hope

Shared from our Instagram Feed.
This is little Aleena. She is from Alberta and has just been diagnosed with MPS VI. The Isaac Foundation will do everything we possibly can to ensure she starts the life-sustaining treatment she so desperately needs.  #Hope